April 22nd 2024
Rhonda Henschel, MBA, discussed the challenges and considerations for community oncology practices looking to implement cellular therapy programs.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Lymphodepletion Improves Results for Allogenic CAR T-Cell Therapy in ALL
January 7th 2022Nitin Jain, MD, discusses the preliminary results of a study investigating allogeneic chimeric antigen receptor T-cell therapy with lymphodepletion in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
Watch
Responses to Cilta-Cel Durable for Nearly 2 Years Across Several R/R Multiple Myeloma Subgroups
December 15th 2021Updated findings from the CARTITUDE-1 trial presented at the 2021 ASH Annual Meeting and Exposition show that the use of a CAR T-cell therapy resulted in durable responses that lasted at nearly 2 years of follow-up across most subgroups with relapsed/refractory multiple myeloma.
Read More
Roundtable Discussion: Persky and Participants Review CAR T-Cell Therapy in DLBCL
October 31st 2021Eleven months after completion of therapy with the R-CHOP regimen, a 43-year-old patient with diffuse large B-cell lymphoma presented with fever, drenching night sweats, and recurrent back pain.
Read More
New Option After Tisagenlecleucel for Patients With R/R LBCL Now in Development
October 20th 2021Following treatment with chimeric antigen receptor T-cell therapy, patients with relapsed or refractory large B-cell lymphoma require more options. Investigators are now evaluating an interleukin-17 agent.
Read More
New Data Solidify Benefit of Loncastuximab Tesirine for Relapsed/Refractory DLBCL
October 1st 2021In an interview with Targeted Oncology, Brad S. Kahl, MD, provided an efficacy update from the LOTUS-2 study and discussed multiple agents showing promise for the treatment of relapsed/refractory diffuse large B-cell lymphoma.
Read More
Exploring CAR T-Cell Therapies in the Indolent Lymphoma Setting
September 10th 2021Early data have shown the promise of CD19-directed chimeric antigen receptor T cells for indolent lymphoma treatment, but longer follow-up is needed to determine if these responses represent cures in these historically difficult-to-treat malignancies.
Read More
Rationale, Data, and Future of Using Ide-Cel CAR T-Cell Therapy
September 1st 2021Larry D. Anderson, Jr, MD, PhD, discusses the rationale behind using chimeric antigen receptor T-cell therapy in relapsed/refractory multiple myeloma, data from the KarMMa trial, and other trials investigating this treatment.
Watch
Clinical Potential of onCARlytics Under Exploration in Solid Tumors
August 4th 2021Research in the solid tumors arena around the combination of the oncolytic virus technology CF33-CD19 and the CD19-targeting CAR placental-derived T-cell therapy CyCART-19, is underway to explore it’s potential in this patient population.
Read More